Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6ZV73

UPID:
FGD6_HUMAN

ALTERNATIVE NAMES:
Zinc finger FYVE domain-containing protein 24

ALTERNATIVE UPACC:
Q6ZV73; Q6ZR53; Q7Z2Z7; Q96D44; Q9NUR8; Q9P2I5

BACKGROUND:
The protein FYVE, RhoGEF, and PH domain-containing protein 6, alternatively named Zinc finger FYVE domain-containing protein 24, is instrumental in the activation of CDC42. This process is essential for the regulation of the actin cytoskeleton and cell morphology, highlighting its pivotal role in cellular architecture and signaling. By facilitating the exchange of GDP for GTP on CDC42, it underscores its potential as a key regulator in cellular dynamics and signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of FYVE, RhoGEF, and PH domain-containing protein 6 offers a promising avenue for the identification of novel therapeutic targets. Given its central role in cellular signaling and structure, targeting this protein could lead to innovative treatments that harness its biological activities for therapeutic advantage.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.